Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage
Carbetocin Administration for the Prevention of Postpartum Hemorrhage in Twin Deliveries: A Randomized Controlled Trial
Sheba Medical Center
120 participants
May 5, 2026
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn if the drug carbetocin works better than standard care to prevent heavy bleeding after childbirth in people carrying twin pregnancies. Heavy bleeding after delivery, also called postpartum hemorrhage, is more common after twin births and can lead to anemia, blood transfusions, and other serious health problems. In this study, bleeding will be evaluated by measuring how much blood hemoglobin levels drop from before delivery to the day after delivery. The main questions this study aims to answer are: * Does giving carbetocin after delivery lower blood loss compared with standard oxytocin treatment? * Is carbetocin safe and practical to use in twin deliveries? Researchers will compare carbetocin to standard oxytocin treatment to see which approach better prevents bleeding after twin vaginal or cesarean delivery. Participants will: * Be randomly assigned to receive either carbetocin or standard oxytocin after the second twin is delivered * Have blood tests before delivery and on the day after delivery * Be followed during their hospital stay and for up to six weeks after delivery for safety outcomes
Eligibility
Inclusion Criteria3
- Pregnant individuals aged ≥18 years
- Twin pregnancies
- Gestational age ≥23 weeks
Exclusion Criteria8
- Known hypersensitivity or contraindication to carbetocin
- Higher-order multiple gestation (triplets or more)
- Maternal age <18 years
- Known placenta accreta spectrum
- Known bleeding disorder
- Intrauterine fetal death of one or more fetuses
- Hyponatremia precluding oxytocin use
- Planned delivery at a non-participating hospital
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Carbetocin will be administered as a single intravenous dose immediately following delivery of the second twin, according to institutional protocol, for the prevention of postpartum hemorrhage.
Oxytocin will be administered intravenously according to standard institutional practice, for the prevention of postpartum hemorrhage.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07401524